Patents Assigned to Discovery Partners, LLC
-
Patent number: 11767334Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.Type: GrantFiled: June 23, 2022Date of Patent: September 26, 2023Assignee: Tetra Discovery Partners, LLCInventors: Mark E. Gurney, Timothy J. Hagen, Xuesheng Mo, A. Samuel Vellekoop, Donna L. Romero, Robert Campbell, Joel R. Walker, Lei Zhu
-
Patent number: 11401286Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.Type: GrantFiled: February 4, 2020Date of Patent: August 2, 2022Assignee: Tetra Discovery Partners, LLCInventors: Mark E. Gurney, Timothy J. Hagen, Xuesheng Mo, A. Samuel Vellekoop, Donna L. Romero, Robert Campbell, Joel R. Walker, Lei Zhu
-
Patent number: 10626129Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.Type: GrantFiled: April 26, 2019Date of Patent: April 21, 2020Assignee: Tetra Discovery Partners, LLCInventors: Mark E. Gurney, Timothy J. Hagen, Xuesheng Mo, A. Samuel Vellekoop, Donna L. Romero, Robert Campbell, Joel R. Walker, Lei Zhu
-
Patent number: 10364258Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.Type: GrantFiled: August 24, 2018Date of Patent: July 30, 2019Assignee: Tetra Discovery Partners, LLCInventors: Mark E. Gurney, Timothy J. Hagen, Xuesheng Mo, A. Samuel Vellekoop, Donna L. Romero, Robert F. Campbell, Joel R. Walker, Lei Zhu
-
Patent number: 10093686Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.Type: GrantFiled: August 18, 2017Date of Patent: October 9, 2018Assignee: Tetra Discovery Partners, LLCInventors: Mark E. Gurney, Timothy J. Hagen, Xuesheng Mo, A. Samuel Vellekoop, Donna L. Romero, Robert F. Campbell, Joel R. Walker, Lei Zhu
-
Patent number: 9777024Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of disease.Type: GrantFiled: November 11, 2015Date of Patent: October 3, 2017Assignee: Tetra Discovery Partners, LLCInventors: Mark E. Gurney, Timothy J. Hagen, Xuesheng Mo, A. Samuel Vellekoop, Donna L. Romero, Robert F. Campbell, Joel R. Walker, Lei Zhu
-
Publication number: 20160274006Abstract: A method and apparatus that serve as a control and calibrator for assays performed on cells and tissues mounted on a microscope slide is described. The apparatus comprises a quality control moiety, such as a peptide epitope, linked to a particulate object, such as a clear spherical bead and the bead is preferably approximately the size of a cell. The quality control moiety is designed to behave in a similar manner in the assay as an analyte, yielding a positive assay reaction an the bead is retained on a microscope slide during the steps of staining by a novel liquid matrix, which solidifies upon drying and causes adherence of the beads to the microscope slide.Type: ApplicationFiled: November 7, 2014Publication date: September 22, 2016Applicant: MEDICAL DISCOVERY PARTNERS LLCInventors: Seshi R. Sompuram, Steven A. Bogen
-
Patent number: 9221843Abstract: The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of disease.Type: GrantFiled: October 24, 2013Date of Patent: December 29, 2015Assignee: Tetra Discovery Partners, LLCInventors: Mark E. Gurney, Timothy J. Hagen, Xuesheng Mo, A. Samuel Vellekoop, Donna L. Romero, Robert F. Campbell, Joel R. Walker, Lei Zhu
-
Patent number: 8865723Abstract: Provided herein are methods of improving cognitive ability or memory in a subject that has suffered a brain injury or spinal cord injury by administering a selective PDE4 B inhibitor.Type: GrantFiled: March 13, 2013Date of Patent: October 21, 2014Assignee: Tetra Discovery Partners LLCInventors: Mark E. Gurney, Coleen M. Atkins, David J. Adaikkalasamy, W. Dalton Dietrich
-
Publication number: 20140121221Abstract: Provided herein are methods of improving cognitive ability or memory in a subject that has suffered a brain injury or spinal cord injury by administering a selective PDE4 B inhibitor.Type: ApplicationFiled: March 13, 2013Publication date: May 1, 2014Applicants: UNIVERSITY OF MIAMI, TETRA DISCOVERY PARTNERS LLCInventors: Mark E. Gurney, Collen M. Atkins, David J. Adaikkalasamy, W. Dalton Dietrich
-
Publication number: 20120283235Abstract: Provided are compositions and methods for treatment of conditions and diseases of the skin, for example fine lines and wrinkles and rosacea. The compositions include a porphyrin that is a chlorophyllin, a chlorin compound, a complex of a chlorin compound, or a salt or ester of the chlorin compound or its complex.Type: ApplicationFiled: October 20, 2010Publication date: November 8, 2012Applicant: DISCOVERY PARTNERS LLCInventors: John P. McCook, Peter L. Dorogi, David B. Vasily
-
Patent number: 8303985Abstract: A therapeutic method is described in which copper is delivered into the skin as a complex with sodium chlorophyllin. Sodium copper chlorophyllin is encapsulated in suitable lecithin-type liposomes, containing a high concentration of linoleic acid and having diameters in the range 150-350 nanometers. The method provides therapeutic benefits in the treatment of environmentally-induced premature skin aging, excessively oily skin, acne and acne-related skin disorders, acne-rosacea, and also stimulates the natural tanning response of skin to sunlight and other ultraviolet-containing radiation.Type: GrantFiled: June 11, 2010Date of Patent: November 6, 2012Assignee: Discovery Partners, LLCInventors: Peter Ladislaus Dorogi, David Bruce Vasily, John Patrick McCook
-
Patent number: 8303984Abstract: This invention discloses compositions and method for treating various types of skin disorders, based on topical cutaneous delivery of copper chemically bound with botanical pigments. Sodium-copper-chlorophyllin is used as an example, showing benefits in the treatment of rosacea, acne, oily skin, enlarged pores, and in relieving skin inflammation. Benefits are also disclosed in treatment of environmentally caused premature skin aging, via reductions in fine facial lines and wrinkles, increased tensile strength of the skin, and increased protection against sunlight via increased production of melanin. Therapeutic outcomes are improved when the copper-pigment complex is enclosed within submicron liposomes.Type: GrantFiled: June 9, 2010Date of Patent: November 6, 2012Assignee: Discovery Partners, LLCInventors: Peter Ladislaus Dorogi, David Bruce Vasily, John Patrick McCook
-
Patent number: 8298555Abstract: This invention discloses color cosmetic compositions and methods for anti-aging treatments that utilize plant-based copper antioxidant complexes.Type: GrantFiled: June 4, 2007Date of Patent: October 30, 2012Assignee: Discovery Partners, LLCInventors: John Patrick McCook, Peter Ladislaus Dorogi, David Bruce Vasily, Deborah Lynn Lydic, David Blair Allen
-
Patent number: 8263404Abstract: An antigen-dependent negative selection blood cell separation method is described. Rare circulating epithelial cells can be separated from blood by depleting erythrocytes from a blood sample. Erythrocytes are depleted by agglutination. The new method comprises the use of an agglutinating agent, such as an anti-glycophorin A or glycophorin B antibody, as glycophorin A or B are present on erythrocytes and not on the desired epithelial cells. With regular mixing, desired rare circulating epithelial cells do not become entrapped in the red cell agglutinate.Type: GrantFiled: April 4, 2006Date of Patent: September 11, 2012Assignee: Medical Discovery Partners LLCInventors: Sarah K. Olken, Steven A. Bogen, Seshi R. Sompuram
-
Publication number: 20090081632Abstract: An antigen-dependent negative selection blood cell separation method is described. Rare circulating epithelial cells can be separated from blood by depleting erythrocytes from a blood sample. Erythrocytes are depleted by agglutination. The new method comprises the use of an agglutinating agent, such as an anti-glycophorin A or glycophorin B antibody, as glycophorin A or B are present on erythrocytes and not on the desired epithelial cells. With regular mixing, desired rare circulating epithelial cells do not become entrapped in the red cell agglutinate.Type: ApplicationFiled: April 4, 2006Publication date: March 26, 2009Applicant: Medical Discovery Partners LLCInventors: Sarah K. Olken, Steven A. Bogen, Seshi R. Sompuram
-
Patent number: 7011940Abstract: The invention describes quality control devices for assays that measure analytes in cells and tissue samples, and methods of use thereof. In particular, the quality control device comprises a matrix affixed with synthetic controls in different concentrations, or different synthetic controls. The quality control device can be adhered to a microscope slide via an adhesive or chemically attached to a microscope slide and processed simultaneously with a tissue sample.Type: GrantFiled: April 14, 2000Date of Patent: March 14, 2006Assignee: Medical Discovery Partners LLCInventors: Seshi R. Sompuram, Halasya Ramanathan, Steven A. Bogen
-
Patent number: 6855490Abstract: The invention describes a method for attaching biological molecules, such as proteins, nucleic acids, and carbohydrates to a glass surface. In particular, a covalent attachment method is described wherein a glass surface is first activated with a water-stable form of an isocyanate, termed a protected isocyanate. The protecting group of the isocyanate moiety is displaced by amines, hydroxyl, or carboxyl groups of biological molecules, leading to covalent attachment to the glass surface.Type: GrantFiled: April 12, 2001Date of Patent: February 15, 2005Assignee: Medical Discovery Partners LLCInventors: Seshi R. Sompuram, Halasya Ramanathan
-
Patent number: 6706257Abstract: Sunless tanning compositions are substantially improved by adding methylsulfonyl methane [MSM] sequentially or simultaneously to compositions containing dihydroxyacetone [DHA].Type: GrantFiled: December 18, 2001Date of Patent: March 16, 2004Assignee: Discovery Partners, LLCInventors: John P. McCook, Philip J. Gordon, D. Craig Woodward